Fusion of mature dendritic cells and human T-lymphotropic virus type I infected T cells: Its efficiency as an antigen-presenting cell

Virology

Volumn 301, Issue 1, 2002, Pages 13-20

  Shimokubo, Satoshi ^a,b   Wakamatsu, Shin Ichi ^b   Maeda, Yumi ^a   Baba, Masanori ^b   Makino, Masahiko ^a,b  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

ATL; DC; Fusion cells; HTLV I

Indexed keywords

8 AZAGUANINE; CD86 ANTIGEN; GAG PROTEIN; HLA ANTIGEN; PHYTOHEMAGGLUTININ;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; BLAST CELL; CELL FUSION; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; NORMAL HUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; VIRUS INFECTION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T-LYMPHOTROPIC VIRUS 1; RNA VIRUSES;

EID: 0036398083     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2002.1546     Document Type: Article

References (39)

1. Boczkowski, D., Nair, S. K., Snyder, D., and Gilboa, E. (1996). Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 184, 465-472.
2. Celluzzi, C. M., Mayordomo, J. I., Storkus, W. J., Lotze, M. T., and Falo, L. D., Jr. (1996). Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J. Exp. Med. 183, 283-287.
3. Condon, C., Watkins, S. C., Celluzzi, C. M., Thompson, K., and Falo, L. D., Jr. (1996). DNA-based immunization by in vivo transfection of dendritic cells. Nat. Med. 2, 1122-1128.
4. Funai, N., Shimamoto, Y., Yoshida, S., Nagai, Y., Nakazato, S., and Kohashi, O. (1996). Differences in immune functions between human T-lymphotropic virus type I carriers and patients with adult T-cell leukemia/lymphoma. Clin. Immunol. Immunopathol. 80, 325-332.
5. Gong, J., Chen, L., Chen, D., Kashiwaba, M., Manome, Y., Tanaka, T., and Kufe, D. (1997a). Induction of antigen-specific antitumor immunity with adenovirus-transduced dendritic cells. Gene Ther. 4, 1023-1028.
6. Gong, J., Chen, D., Kashiwaba, M., and Kufe, D. (1997b). Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat. Med. 3, 558-561.
7. Gong, J., Chen, D., Kashiwaba, M., Li, Y., Chen, L., Takeuchi, H., Qu, H., Rowse, G. J., Gendler, S. J., and Kufe, D. (1998). Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc. Natl. Acad. Sci. USA 95, 6279-6283.
8. Gong, J., Avigan, D., Chen, D., Wu, Z., Koido, S., Kashiwaba, M., and Kufe, D. (2000a). Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc. Natl. Acad. Sci. USA 97, 2715-2718.
9. Gong, J., Nikrui, N., Chen, D., Koido, S., Wu, Z., Tanaka, Y., Cannistra, S., Avigan, D., and Kufe, D. (2000b). Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J. Immunol. 165, 1705-1711.
10. Hino, S., Yamaguchi, K., Katamine, S., Sugihara, H., Amagasaki, T., Kinoshita, K., Yoshida, Y., Doi, H., Tsuji, Y., and Miyamoto, T. (1985). Mother-to-child transmission of human T-cell leukemia virus type-I. Jpn. J. Cancer Res. 76, 474-480.
11. Hollsberg, P., and Hafler, D. A. (1993). Seminars in medicine of the Beth Israel Hospital, Boston. Pathogenesis of diseases induced by human lymphotropic virus type I infection. N. Engl. J. Med. 328, 1173-1182.
12. Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G., and Levy, R. (1996). Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2, 52-58.
13. + cytotoxic T lymphocytes by dendritic cells. J. Exp. Med. 166, 182-194.
14. Inaba, K., Metlay, J. P., Crowley, M. T., and Steinman, R. M. (1990). Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ. J. Exp. Med. 172, 631-640.
15. + cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature 348, 245-248.
16. Kannagi, M., Sugamura, K., Sato, H., Okochi, K., Uchino, H., and Hinuma, Y. (1983). Establishment of human cytotoxic T cell lines specific for human adult T cell leukemia virus-bearing cells. J. Immunol. 130, 2942-2946.
17. + cytotoxic T cells directed against HTLV-I-infected cells. Int. Immunol. 3, 761-767.
18. Kugler, A., Stuhler, G., Walden, P., Zöller, G., Zobywalski, A., Brossart, P., Trefzer, U., Ullrich, S., Müller, C. A., Becker, V., Gross, A. J., Hemmerlein, B., Kanz, L., Müller, G. A., and Ringert, R. H. (2000). Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat. Med. 6, 332-336.
19. Kusuhara, K., Sonoda, S., Takahashi, K., Tokunaga, K., Fukushige, J., and Ueda, K. (1987). Mother-to-child transmission of human T-cell leukemia virus type-I (HTLV-I): A fifteen-year follow-up study in Okinawa, Japan. Int. J. Cancer 40, 755-757.
20. Lespagnard, L., Mettens, P., Verheyden, A-M., Tasiaux, N., Thielemans, K., van Meirvenne, S., Geldhof, A., De Baetselier, P., Urbain, J., Leo, O., and Moser, M. (1998). Dendritic cells fused with mastocytoma cells elicit therapeutic antitumor immunity. Int. J. Cancer 76, 250-258.
21. Makino, M., and Baba, M. (1997). A cryopreservation method of human peripheral blood mononuclear cells for efficient production of dendritic cells. Scand. J. Immunol. 45, 618-622.
22. Makino, M., Shimokubo, S., Wakamatsu, S., Izumo, S., and Baba, M. (1999). The role of human T-lymphotropic virus type 1 (HTLV-1)-infected dendritic cells in the development of HTLV-1-associated myelopathy/tropical spastic paraparesis. J. Virol. 73, 4575-4581.
23. Makino, M., Wakamatsu, S., Shimokubo, S., Arima, N., and Baba, M. (2000). Production of functionally deficient dendritic cells from HTLV-I-infected monocytes: Implications for the dendritic cell defect in adult T cell leukemia. Virol. 274, 140-148.
24. Makino, M., Utsunomiya, A., Maeda, Y., Shimokubo, S., Izumo, S., and Baba, M. (2001). Association of CD40 ligand expression on HTLV-I-infected T cells and maturation of dendritic cells. Scand. J. Immunol. 54, 574-581.
25. Mayordomo, J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Celluzzi, C., Falo, L. D., Melief, C. J., Ildstad, S. T., Kast, W. M., Deleo, A. B., and Lotze, M. T. (1995). Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1, 1297-1302.
26. Nakano, S., Ando, T., Saito, K., Moriyama, I., Ichijo, M., Toyama, T., Sugamura, K., Imai, J., and Hinuma, Y. (1986). Primary infection of Japanese infants with adult T-cell leukemia-associated retrovirus (ATLV): evidence for virus transmission from mother to children. J. Infect. Dis. 12, 205-212.
27. Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., and Schadendorf, D. (1998). Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4, 328-332.
28. + T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia. Blood 91, 977-983.
29. Paglia, P., Chiodoni, C., Rodolfo, M., and Colombo, M. P. (1996). Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183, 317-322.
30. Ribas, A., Butterfield, L. H., McBride, W. H., Jilani, S. M., Bui, L. A., Vollmer, C. M., Lau, R., Dissette, V. B., Hu, B., Chen, A. Y., Glaspy, J. A., and Economou, J. S. (1997). Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. Cancer Res. 57, 2865-2869.
31. Song, E. S., Lee, V., Surh, C. D., Lynn, A., Brumm, D., Jolly, D. J., Warner, J. F., and Chada, S. (1997a). Antigen presentation in retroviral vector-mediated gene transfer in vivo. Proc. Natl. Acad. Sci. USA 94, 1943-1948.
32. Song, W., Kong, H. L., Carpenter, H., Torii, H., Granstein, R., Rafii, S., Moore, M. A. S., and Crystal, R. G. (1997b). Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J. Exp. Med. 186, 1247-1256.
33. Specht, J. M., Wang, G., Do, M. T., Lam, J. S., Royal, R. E., Reeves, M. E., Rosenberg, S. A., and Hwu, P. (1997). Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J. Exp. Med. 186, 1213-1221.
34. + T cells susceptible to HTLV-I infection in a costimulatory molecule-dependent fashion. Eur. J. Immunol. 27, 1427-1432.
35. Takatsuki, K., Uchiyama, T., Sagawa, K., and Yodoi, J. (1977). Adult T cell leukemia in Japan. In "Topics in Hematology" (S. Seno, F. Takaku, and S. Irino, Eds.), pp. 73-77. Excerota Medica, Amsterdam.
36. Uchiyama, T., Yodoi, J., Sagawa, K., Takatsuki, K., and Uchino, H. (1977). Adult T-cell leukemia: Clinical and hematologic features of 16 cases. Blood 50, 481-492.
37. Uchiyama, T. (1997). Human T cell leukemia virus type I (HTLV-I) and human diseases. Annu. Rev. Immunol. 15, 15-37.
38. Wang, J., Saffold, S., Cao, X., Krauss, J., and Chen, W. (1998). Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J. Immunol. 161, 5516-5524.
39. Weber, J., Salgaller, M., Samid, D., Johnson, B., Herlyn, M., Lassam, N., Treisman, J., and Rosenberg, S. A. (1994). Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2′-deoxycytidine. Cancer Res. 54, 1766-1771.